The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
The Land Transportation Office (LTO) said there is no law authorizing local government unit (LGU) traffic
The Philippines and the United States have signed a five-year Health Strategic Objective Agreement that will
Lawyer Manases “Mans” Carpio, husband of Vice President Sara Duterte, questioned the legality of the authorization
Health Secretary Jose “Brix” Pujalte Jr. denied allegations that he engaged in gambling, saying his visit
The Philippine Drug Enforcement Agency (PDEA) and the Bureau of Internal Revenue (BIR) signed a Data